1.Enumerate the rate of hospice live discharges associated with subsequent opioid dependence.2.Identify patient and provider trends in the rate of opioid dependence incidents after hospice live discharge. Medicare beneficiaries that elect the Medicare Hospice benefit often receive opioids as a standard medication to treat pain. Little is known about the prevalence of opioid dependence following live discharge from hospice. The Centers for Medicare & Medicaid Services Chronic Care Policy Group seeks to examine live discharges associated with subsequent opioid dependence and identify patient and provider characteristics of such discharges. Retrospective cohort analysis of Medicare hospice discharges during Federal Fiscal Years 2017-18 (FY2017-2018). Using 100% Medicare inpatient and Part B claims, we identified ICD-10 codes indicating opioid dependence indicated by a crosswalk maintained by the Agency for Healthcare Research and Quality. There were 2,673,218 hospice discharges FY2017-FY2018, of which 468,204 (17.5%) were live discharges. Among these, 9,282 discharges (2.0%) were associated with 28,962 opioid-related diagnoses after discharge. Approximately one quarter (26.4%) of these diagnoses appeared on inpatient claims. The states with the highest rates of opioid-related post-discharge incidents per 10,000 hospice live discharges were Kentucky (435.2), Wyoming (386.0), Tennessee (359.3), Washington (345.6), and Idaho (342.9). Post-hospice opioid diagnoses were more likely if the beneficiary was younger (for ages <65 relative to 85-89, AOR=6.23, 95% CI 5.73-6.77); dual-eligible (AOR=1.40, 95% CI 1.34-1.47); and relative to cancer, being diagnosed at admission with COPD (AOR=1.83, 95% CI 1.72-1.95), heart diseases (CHF: AOR=1.23, 95% CI 1.14-1.34; Other Heart Disease: AOR=1.23, 95% CI 1.14-1.33), or liver disease (AOR=1.25, 95% CI 1.10-1.42). There were no discernable patterns among hospice characteristics. Opioid dependence after hospice was more frequent among beneficiaries who were younger, dual-eligible, diagnosed with COPD, heart, or liver diseases, or residing in the lower Appalachian and Northwestern states.
Read full abstract